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THE ELUSIVE SOURCE OF HIV-1 REBOUND AFTER TREATMENT INTERRUPTION 
Participant STAR 11: Intact proviruses integrated in genes regulating
transcription and tumor growth
• 99 IS and 107 proviral genomes were sequenced yielding 14 intact
proviruses (13%) with the highest proportion found in the TEM subset
(n=13, 45%).
• Four different clusters of identical sequences could be identified of
which 2 consisted of intact TEM sequences respectively linked to an IS
in ZNF274 (8% of all IS) and GGNBP2 (3% of all IS).
Participant STAR 10:  Defective proviruses match the env region of rebounding 
plasma virus
• 149 IS and 132 proviral genomes were sequenced while only 3 unique intact 
proviruses (2%) were identified. 
• A cluster of 17 identical defective proviruses were linked to an IS (9% of all IS) in 
STAT5B located in TNA, TTM and TCM.
• Comparing trimmed FLIPS to SGS V1V3 env sequences, two 100% matches were 
found between a defective provirus (large internal deletion or ψ deletion) and a 
plasma HIV RNA sequence during rebound.
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BACKGROUND
The goal is to identify the source of viral rebound during a
monitored analytical treatment interruption (ATI) in the STAR
cohort by examining the genetic composition of proviral
DNA in different subsets from participants on antiretroviral
therapy and compare this to rebounding virus after ATI.
METHODS
• Eleven participants were sampled from different
anatomical sites (peripheral blood, lymph nodes (LN)
and gut-associated lymphoid tissue (GALT)) prior to and
during ATI.
• Single-genome sequencing (SGS) of V1V3 env region of
plasma-derived RNA was performed (De Scheerder et
al., CELL HOST & MICROBE, 2019).
In an ongoing study, Full-Length Individual Proviral
Sequencing (FLIPS), Integration Site Loop Amplification
(ISLA) and modified matched integration site and proviral
sequencing (MIP-Seq) assays were performed on the T cell
subsets from 3 participants.
RESULTS
Participant STAR 9: Identical hypermutated provirus found 
across different memory T cell subsets
• 126 IS and 127 proviral genomes were sequenced, only 3 
unique intact proviruses (2%) were identified. 
• No link with integration site (IS) due to failure of V1V3 SGS 
caused by primer mismatching.
• 15 (52%) of the 29 hypermutated sequences are identical 
and distributed over different memory subsets: 4 in TCM 
(27%), 5 in TTM (33%) and 6 in TEM (40%). 
CONCLUSIONS
• The proviral landscape across different participants is highly variable as illustrated in these three HIV-1 infected individuals.
• Determining the source of viral rebound based on the analysis of subgenomic regions should be interpreted with caution as illustrated in participant STAR10.
STAR11 STAR10
A. B.
Figure 3: Maximum likelihood tree of all proviral STAR 11 FLIPS sequences. Inner circle layer showing
identical sequences based on FLIPS alignment. Middle circle layer displaying matching V1V3 env between
trimmed FLIPS proviruses and MIP-Seq SGS V1V3 sequences, suggesting link between IS and FLIPS
provirus. Outer circle layer showing genetic characterization based on FLIPS sequences.
Figure 4: Maximum likelihood tree of all proviral STAR10 FLIPS sequences A) Inner circle layer showing identical sequences based
on FLIPS alignment. Middle circle layer displaying matching V1V3 env between trimmed FLIPS proviruses and MIP-Seq SGS V1V3
sequences, suggesting link between IS and FLIPS provirus. Outer circle layer showing genetic characterization based on FLIPS
sequences. B) Tree showing unique V1V3 sequences from trimmed FLIPS and V1V3 SGS on plasma from rebound.
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Figure 2: A. Integration Sites recovered via ISLA. B. Schematic overview of the FLIPS
sequences.
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